Pluri (PLUR) AI Stock Analysis

• Market Cap: $36.42M
• Dividend Yield: N/A
• Average Volume (3M): 9.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: 309.82%
• EPS Growth: 11.80%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.68
• Shares Outstanding: 8,155,948
• 10 Day Avg. Volume: 5,062
• 30 Day Avg. Volume: 9,961
• PEG Ratio: 1.25
• Price to Book (P/B): -45.85
• Price to Sales (P/S): 234.79
• P/FCF Ratio: -15.82
• Enterprise Value/Market Cap: 1.18
• Enterprise Value/Revenue: 41.68
• Enterprise Value/Gross Profit: 90.17
• Enterprise Value/Ebitda: -2.13
• 1Y Price Target: $8.50
• Price Target Upside: 82.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: $4.50 ▼(-3.23% Downside)

Pluri's overall stock score is primarily impacted by its poor financial performance and valuation concerns. The technical analysis also indicates weak market momentum, further contributing to the low score. Strategic improvements are necessary to enhance financial stability and investor confidence.

Pluri Business Overview & Revenue Model

Company Description

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

How the Company Makes Money

Pluri generates revenue primarily through the sale of its software solutions and platform subscriptions. The company offers various pricing tiers, enabling it to cater to both small businesses and large enterprises. Additionally, Pluri forms strategic partnerships with other technology providers to enhance its product offerings and expand its market reach, which also contributes to its revenue streams. The company's earnings are further supported by consulting and support services provided to its clients, ensuring successful implementation and ongoing utilization of its software solutions.

Pluri Financial Statement Overview

Summary

Pluri faces significant financial challenges with persistent losses, negative equity, and weak cash flow. Despite revenue growth, the company's financial health remains precarious, requiring strategic changes to achieve stability and profitability.

Income Statement

Pluri's income statement reveals significant challenges with profitability. Despite a notable revenue growth rate of 29.21% in the latest year, the company struggles with negative net profit margins and EBIT margins, indicating ongoing losses. The gross profit margin has improved but remains insufficient to offset high operating expenses.

Balance Sheet

The balance sheet shows a concerning financial structure with negative stockholders' equity and a high debt-to-equity ratio in recent years. Although the debt-to-equity ratio improved in the latest year, the negative equity and low return on equity highlight financial instability and potential solvency risks.

Cash Flow

Pluri's cash flow statement indicates some improvement in free cash flow growth, but operating cash flow remains negative. The free cash flow to net income ratio suggests that cash flow is slightly better than net income figures, yet the overall cash flow position is weak, reflecting ongoing operational challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.03M	1.34M	326.00K	287.00K	234.00K	0.00
Gross Profit	478.00K	654.00K	322.00K	278.00K	-819.00K	-1.37M
EBITDA	-20.22M	-23.33M	-20.23M	-27.68M	-39.43M	-48.42M
Net Income	-20.71M	-23.25M	-20.89M	-28.32M	-41.24M	-49.87M
Balance Sheet
Total Assets	37.41M	16.59M	39.53M	50.80M	68.06M	93.54M
Cash, Cash Equivalents and Short-Term Investments	26.27M	5.89M	30.24M	40.17M	55.02M	64.95M
Total Debt	31.19M	6.76M	29.61M	29.91M	28.80M	24.58M
Total Liabilities	36.92M	7.22M	34.11M	35.50M	35.88M	36.39M
Stockholders Equity	-4.47M	-6.84M	96.00K	13.36M	30.04M	57.15M
Cash Flow
Free Cash Flow	-18.21M	-19.83M	-18.34M	-23.12M	-36.78M	-31.28M
Operating Cash Flow	-17.31M	-18.21M	-18.02M	-22.86M	-36.50M	-30.91M
Investing Cash Flow	193.00K	8.03M	10.58M	9.70M	11.78M	-7.26M
Financing Cash Flow	18.81M	9.53M	8.84M	8.02M	7.50M	61.40M

Pluri Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLUR, the sentiment is Negative. The current price of 4.65 is below the 20-day moving average (MA) of 4.83, below the 50-day MA of 4.97, and below the 200-day MA of 4.71, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 43.77 is Neutral, neither overbought nor oversold. The STOCH value of 14.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PLUR.

Pluri Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLNN	58 Neutral	59.21M	-2.26	444.85%	―	-35.29%	45.18%
DARE	46 Neutral	28.17M	-4.73	67.43%	―	88.13%	92.45%
GDTC	41 Neutral	23.35M	-12.18	―	―	―	38.80%
PLUR	41 Neutral	$36.42M	―	-1205.58%	―	309.82%	11.80%
TPST	39 Underperform	41.65M	-0.64	―	―	―	3.39%
NRSN	30 Underperform	30.51M	-2.12	―	―	―	31.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Pluri Corporate Events

Pluri’s 2025 Annual Meeting Decisions Announced

On June 30, 2025, Pluri held its 2025 Annual Meeting where shareholders voted on several proposals. Key decisions included the election of directors, ratification of the accounting firm Kesselman & Kesselman, approval of the 2016 Equity Compensation Plan, and the determination that future advisory votes on executive compensation will occur every two years. Additionally, the approval of the exercise of warrants related to a private placement offering was confirmed, excluding shares owned by Mr. Alexandre Weinstein.

The most recent analyst rating on (PLUR) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Pluri stock, see the PLUR Stock Forecast page.

Pluri Regains Nasdaq Compliance Before Deadline

Pluri Inc. received a deficiency letter from Nasdaq on November 25, 2024, for not meeting the stockholders’ equity requirement or alternative listing standards. After submitting a compliance plan, Nasdaq granted an extension until May 24, 2025. By May 7, 2025, Pluri regained compliance by maintaining a market value of $35 million for 10 consecutive days, ensuring its continued listing on The Nasdaq Capital Market.